Welcome to our dedicated page for vTv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on vTv Therapeutics stock.
vTv Therapeutics Inc. reports developments as a late-stage biopharmaceutical company focused on oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a liver-selective glucokinase activator being investigated as an oral adjunctive therapy to insulin for type 1 diabetes. Company updates also reference development work and partnerships across additional chronic-disease candidates, including the PDE4 inhibitor HPP737.
Recurring announcements include clinical and regulatory updates for cadisegliatin, financial results and corporate updates, license and collaboration activity, investor-conference participation, and Nasdaq inducement grants under equity compensation plans. News about vTv often connects pipeline progress with funding arrangements, intellectual property, and business-development agreements that support its drug-development strategy.
vTv Therapeutics (VTVT) granted stock options to purchase 2,500 shares of common stock to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $31.44 per share, a 10-year term, and vest over 4 years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remainder vesting quarterly over the following 36 months, subject to continued employment. The grant is made under the company’s 2026 Inducement Plan and a related stock option agreement. vTv is a late-stage biopharmaceutical company whose lead candidate, cadisegliatin (TTP399), is in a US Phase 3 trial for type 1 diabetes and has FDA Breakthrough Therapy designation.
vTv Therapeutics (VTVT) will participate in two investor conferences in September 2026 to discuss its late-stage work on cadisegliatin, an oral investigational therapy for type 1 diabetes. Management will join a fireside chat and one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 16 in New York and hold one-on-one investor meetings at the 5th Annual ROTH Healthcare Opportunities Conference on September 29.
vTv Therapeutics (Nasdaq: VTVT) granted 2,500 stock options to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $31.48 per share, a 10-year term, and vest over four years, with 25% vesting after one year and the remainder vesting quarterly over the next 36 months, subject to continued employment.
The grant is made under the company’s 2026 Inducement Plan. vTv is a late-stage biopharmaceutical company whose clinical pipeline is led by cadisegliatin (TTP399), an oral glucokinase activator in a US Phase 3 trial for type 1 diabetes and granted FDA Breakthrough Therapy designation.
vTv Therapeutics (Nasdaq: VTVT) reported second quarter 2026 results and a corporate update centered on cadisegliatin for type 1 diabetes (T1D). Enrollment in the Phase 3 CATT1 trial, evaluating cadisegliatin as an oral adjunctive therapy to insulin, is expected to complete in the third quarter of 2026. A Phase 2a Hybrid CATT1 trial in T1D patients using hybrid closed-loop insulin delivery is expected to initiate before year end 2026, and a KOL event focused on T1D and cadisegliatin is planned for the fourth quarter of 2026.
Cash and cash equivalents were $86.6 million at June 30, 2026, which vTv expects will fund operations through the anticipated CATT1 topline readout. For Q2 2026, R&D expenses were $8.8 million, G&A $5.2 million, and net loss attributable to shareholders was $13.1 million, or $1.05 per basic and diluted share. Six‑month 2026 revenue totaled $36.8 million. Stockholders’ equity increased to $78.6 million versus $64.4 million at December 31, 2025.
vTv Therapeutics (Nasdaq: VTVT) granted stock options to two non-executive employees as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4). The awards cover 23,500 options with a weighted average exercise price of $31.95 per share and a 10-year term.
Each option vests over 4 years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remainder vesting quarterly over the following 36 months, subject to continued employment and the 2026 Inducement Plan terms. vTv highlights its late-stage pipeline led by cadisegliatin (TTP399), a liver-selective glucokinase activator in a US Phase 3 trial for type 1 diabetes, which has FDA Breakthrough Therapy designation.
vTv Therapeutics (Nasdaq: VTVT) granted 12,500 stock options to two non-executive employees as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
The options have a weighted average exercise price of $34.15, vest over 4 years, carry a 10-year term, and are issued under the 2026 Inducement Plan.
vTv Therapeutics (Nasdaq: VTVT) granted stock options as a material inducement to a new non-executive employee under Nasdaq Listing Rule 5635(c)(4).
The grant covers 2,500 options at an exercise price of $34.30, vesting over four years, with a 10-year term under the 2026 Inducement Plan.
vTv Therapeutics (Nasdaq: VTVT) reported Q1 2026 revenue of $36.8 million and net income attributable to shareholders of $24.1 million, or $1.94 basic and $1.65 diluted EPS.
Cash and equivalents were $98.1 million, supported by a $20 million upfront payment from a Newsoara license amendment. Phase 3 CATT1 enrollment for cadisegliatin in type 1 diabetes remains on track to complete in Q3 2026, with cash expected to fund operations through topline data.
vTv Therapeutics (Nasdaq: VTVT) granted 39,500 stock options as material inducements to two non-executive employees under Nasdaq Listing Rule 5635(c)(4).
The options carry a weighted average exercise price of $32.00 per share, vest over four years (25% after one year, then quarterly over 36 months), have a 10-year term, and are governed by the 2026 Inducement Plan and individual option agreements.
vTv Therapeutics (Nasdaq: VTVT) said management will attend two investor conferences in May 2026: H.C. Wainwright BioConnect in New York on May 19, 2026 and Alliance Global Partners Healthcare Company Showcase (virtual) on May 20, 2026.
Live fireside chat webcasts and replays will be available on the company website's Media & Events section.